Listening and learning remains the key to personalising therapy, says Jan Vermorken, who spent a career specialising in the cruellest of cancers. Download full article
Prognostic models for patients with Hodgkin lymphoma are imperfect and do not allow a precise individualised therapy. A recent gene-expression profiling study, translated into a routine immunohistological test, identified genes of tumour-associated macrophages as being [more]
The number of drugs being developed to target specific mutations is rising steadily. But finding which targeted therapies work best for which sets of mutations is proving an elusive goal. Download full article
Too slow, too expensive, too ineffective. Researchers are crying out for a new battle plan that will aim high and deliver on the great promise of personalised therapies. We all want to see target patient [more]
Recent years have seen a scramble to identify the genetic variance that predisposes or protects against certain cancers and the tumour gene signatures that could indicate which therapies will work and which won’t. A picture [more]
New technologies offer wonderful possibilities for cancer patients. But the development of personalised therapies is being squeezed between the priorities of industry and a regulatory system that offers poor value for money. Is there a [more]
Personal genetic signatures may help assess a person’s risk of getting cancer, predict risk of recurrence, or identify the best treatment for them. At a Meet the Experts session, nine ASCO luminaries explained to press [more]